Integra Lifesciences Holdings Corp (IART): John Mooradian , Corp VP, Global Ops & Supp Chn of Integra Lifesciences Holdings Corp sold 7,653 shares on Jun 5, 2015. The Insider selling transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were sold at $67.04 per share for a total value of $532,787.38 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Joseph Vinhais (Corp VP,Global Qlty Assurance) sold 972 shares at $73.36 per share price.On May 6, 2016, Glenn Coleman (CVP, CHIEF FINANCIAL OFFICER) sold 3,563 shares at $70.62 per share price.Also, On May 5, 2016, Christian S Schade (director) sold 7,829 shares at $70.42 per share price.On May 4, 2016, Daniel L. Reuvers (Corp VP, Pres. International) sold 1,000 shares at $71.43 per share price.
Shares of Integra Lifesciences Holdings Corp (IART) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.26 points or -0.36% at $72.95 with 4,59,234 shares getting traded. Post opening the session at $73.48, the shares hit an intraday low of $72.3 and an intraday high of $73.48 and the price vacillated in this range throughout the day. The company has a market cap of $2,715 M and the number of outstanding shares has been calculated to be 3,72,18,896 shares. The 52-week high of Integra Lifesciences Holdings Corp is $73.75 and the 52-week low is $54.75.
Company has been under the radar of several Street Analysts.Integra Lifesciences Holdings Corp is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 74 from a previous price target of $70 .The Rating was issued on Apr 28, 2016.
Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.